Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration

References

• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485–9.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423–33.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53.
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000067.
   Google Scholar
• Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000545.
   Google Scholar
• Elion GB. The pharmacology of azathioprine. Ann NY Acad Sci 1993;685:400–7.
   PubMed Web of Science ®Google Scholar
• Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642–6.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–13.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047–53.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940–87.
   PubMed Web of Science ®Google Scholar
• Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740–6.
   PubMed Web of Science ®Google Scholar
• Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008;23:1373–7.
   PubMed Web of Science ®Google Scholar
• Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000;135:256–62.
   PubMed Web of Science ®Google Scholar
• Jobson B, Garza A, Sninsky A. Red cell mean corpuscular volume (MCV) correlates with 6 thioguanine nucleotide (6TG) levels during azathioprine or 6-MP therapy for Crohn's disease (abstract). Gastroenterology 2001;120(Suppl 1):A4.
   Google Scholar
• Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71–6.
   PubMed Web of Science ®Google Scholar
• Thomas CW Jr, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003;9:237–45.
   PubMed Web of Science ®Google Scholar
• D'Halluin PN, Tribut O, Branger B, Lebreton C, Bretagne JF, Bentue-Ferrer D, RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol Clin Biol 2005;29:1264–9.
   PubMedGoogle Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–6.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591–2.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Systemic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29–42.
   PubMed Web of Science ®Google Scholar
• Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83–90.
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163: 670–5.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe SN, Dodsworth H, Rault RM, Hulme B. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974;18:443–6.
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813–21.
   PubMed Web of Science ®Google Scholar
• McGrath BP, Ibels LS, Raik E, Hargrave MJ. Erythroid toxicity of azathioprine. Macrocytosis and selective marrow hypoplasis. Q J Med 1975;44:57–63.
   PubMedGoogle Scholar
• Revel-Vilk S, Tamary H, Broide E, Zoldan M, Dinari G, Zahavi I, Serum transferrin receptor in children and adolescents with inflammatory bowel disease. Eur J Pediatr 2000;159:585–9.
   PubMedGoogle Scholar
• Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006;101:2769–76.
   PubMed Web of Science ®Google Scholar
• Heckmann JM, Lambson EM, Little F, Owen EP. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 2005;231:71–80.
   PubMed Web of Science ®Google Scholar
• Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009;24:1258–64.
   PubMed Web of Science ®Google Scholar
• Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49: 665–70.
   PubMed Web of Science ®Google Scholar
• Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99:1744–8.
   PubMed Web of Science ®Google Scholar